Skip to content

Project 3, Study 2: Extended Exposure to Low Nicotine Content Cigarettes in People With Current Affective Disorders

Project 3, Study 2: Extended Exposure to Low Nicotine Content Cigarettes in People With Current Affective Disorders

Status
Completed
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02232737
Enrollment
775
Registered
2014-09-05
Start date
2016-10-07
Completion date
2019-01-14
Last updated
2022-12-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tobacco Use Disorder

Keywords

Biomarkers of exposure, Compensatory smoking, Nicotine dependence, Reduced nicotine cigarettes, Tobacco withdrawal, Women, Health disparities, Vulnerable populations

Brief summary

This study will examine extended exposure to cigarettes varying in nicotine content among disadvantaged women. Adults with affective disorders are at increased risk for smoking, nicotine dependence, and using high nicotine yield cigarettes and are also at significantly increased risk for smoking-related adverse health consequences, including site-specific cancers, heart disease, and premature death. Studies testing an innovative regulatory strategy of reducing the nicotine content of cigarettes to a non-addictive level have shown promising beneficial effects (decreased smoking rate, reduced toxicant exposure, and increased cessation) in the general population of smokers. However, these studies have uniformly excluded vulnerable populations like those with affective disorders who may respond differently considering their greater vulnerability to smoking and nicotine dependence. Thus, little is known scientifically about how this highly vulnerable subgroup of smokers might respond to a nicotine reduction policy. This project is designed to address that substantial knowledge gap. This same study was also conducted in two additional vulnerable populations under a similar protocol.

Detailed description

The primary overall objective of these studies is to evaluate the effects of extended exposure to cigarettes differing in nicotine content in adult men and women with affective disorders using a 3-condition, parallel groups design. After a baseline period in which daily smoking rate and other baseline assessments are completed, participants will be randomly assigned to one of three cigarette conditions (nicotine content: 0.03, 0.12, and 0.8 mg nicotine of tobacco) for the 12-week experimental period. The cigarettes to be used in this study were made under an NIH contract with production being overseen by the Research Triangle Institute (referred to as Spectrum cigarettes). NIH currently has approximately 10 million of these cigarettes (of varying types) for research purposes. The cigarettes selected for the study span the range of yields likely to produce the hypothesized effects, as described above. The Spectrum cigarettes are not currently commercially available, although they are similar in many ways to marketed cigarettes (e.g., similar manufacturing, filter, paper, etc.). The primary overall objective of this study is to evaluate the effects of extended exposure to cigarettes differing in nicotine content in adult men and women with affective disorders using a 3-condition, parallel groups design. After a baseline period in which daily smoking rate and other baseline assessments are completed, participants will be randomly assigned to one of three cigarette conditions (nicotine content: 0.03 mg, 0.12 mg, and 0.8 mg nicotine of tobacco) for the 12-week experimental period. Participants will be seen weekly throughout the 12-week experimental period to obtain research cigarettes. Cigarettes smoked per day will be obtained by participants completing daily Interactive Voice Response (IVR) reports of cigarettes in past 24 hours. This daily data will be used to calculate weekly means, with week-12 means serving as the primary outcome. This same study was conducted in two additional vulnerable populations under a similar protocol, with differences between protocols consisting of data collection specific to that vulnerable population. This included information such as use and timing of opioid maintenance therapy for individuals with opioid-use disorder and other measures relevant to disadvantaged women of reproductive age. In order to explore potential differences across individuals with different vulnerabilities, data from all three studies were combined for analysis. A vulnerable population-by-condition or population-by-condition-by-time interaction term was included in all analyses. In the event that these interaction terms were statistically significant, all pairwise comparisons were conducted using a Bonferroni multiple comparison adjustment.

Interventions

Sponsors

University of Vermont
CollaboratorOTHER
National Institute on Drug Abuse (NIDA)
CollaboratorNIH
Brown University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)

Intervention model description

This study was one of three multi-site clinical trials conducted in three different vulnerable populations under a similar protocol, with differences between protocols consisting of data collection specific to that vulnerable population. This included information such as use and timing of opioid maintenance therapy for individuals with opioid-use disorder or additional assessments related to disadvantaged women of reproductive age. In order to explore potential differences across individuals with different vulnerabilities, data from all three studies were combined for analysis. A vulnerable population-by-condition or population-by- condition-by-time interaction term was included in all analyses. In the event that these interaction terms were statistically significant, all pairwise comparisons were conducted using a Bonferroni multiple comparison adjustment. Please see Statistical Analysis Plan for more details.

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* Male or Female * Ages 18-70 * Past-year major depressive disorder, dysthymic disorder, generalized anxiety disorder, post-traumatic stress disorder, obsessive-compulsive disorder, phobia, or panic disorder with or without agoraphobia, based on Mini-Neuropsychiatric Interview (MINI) structured interview, OR lifetime diagnosis of one of the above based on MINI with a self-report of currently receiving treatment (prescribed psychoactive medication, behavioral therapy, etc.) * Report smoking 5 or more cigarettes per day for the past year * Provide an intake breath Carbon Monoxide (CO) sample \> 8 ppm * Be without current substance abuse/dependence other than nicotine * Be sufficiently literate to complete the research-related tasks * Be in good physical health without serious illness or change in health in the past 3 months as determined by the licensed medical professional at each site * Not pregnant or nursing and report using oral, implant, patch, ring, intrauterine device (IUD), injection or barrier contraceptives or report being surgically sterile or post-menopausal * Report no significant use of other tobacco or nicotine products within the past month (\> 9 days in the past 30)

Exclusion criteria

* Any prior regular use (used as primary cigarette outside of the laboratory) of Spectrum cigarettes (i.e., research cigarettes with reduced nicotine content) * Exclusive use of roll-your-own cigarettes * Planning to quit smoking in the next 30 days * A quit attempt in the past 30 days resulting in \> 3 days of abstinence * Positive toxicology screen for illicit drugs not including marijuana (participants with valid prescriptions will not be excluded and participants with a positive toxicology screen will be allowed to re-screen once) * Breath alcohol level \> 0.01 (participants with a positive screen will be allowed to re-screen once) * Self-report of binge drinking alcohol (\> 9 days in the past 30, 4/5 drinks in 2 hours for women/men * Systolic blood pressure below 90 mmHg or greater than or equal to 160 mmHg (participants outside the range will be allowed to re-screen once) * Diastolic blood pressure below 50 mmHg or greater than or equal to 100 mmHg (participants outside the range will be allowed to re-screen once) * Breath CO \> 80 ppm * Heart rate below 45 or greater than or equal to 115 bpm (participants outside the range will be allowed to re-screen once) * Currently seeking treatment for smoking cessation * Have used nicotine replacement, bupropion or other pharmacotherapies as cessation aids in the past month (bupropion for treatment of depression will be allowed) * Unstable psychiatric conditions (psychiatric medication changes in the past 4 weeks) * Current symptoms of psychosis, dementia or mania * Suicidal ideation in past month * Suicide attempt in past 6 months * Participation in another research study in the past 30 days

Design outcomes

Primary

MeasureTime frameDescription
Cigarettes Per Day (CPD)12 weeksParticipant reported number of cigarettes smoked per day at Week 12

Countries

United States

Participant flow

Participants by arm

ArmCount
0.8 mg Nicotine
0.8 mg nicotine cigarettes Very low nicotine content cigarettes
254
0.12 mg Nicotine
0.12 mg nicotine cigarettes Very low nicotine content cigarettes
235
0.03 mg Nicotine
0.03 mg nicotine cigarettes Very low nicotine content cigarettes
286
Total775

Withdrawals & dropouts

PeriodReasonFG000FG001FG002
Overall StudyAdverse Event638
Overall StudyDeath011
Overall StudyIncarcerated212
Overall StudyLost to Follow-up182833
Overall StudyPersonal reasons7814
Overall StudyPhysician Decision131
Overall StudyProtocol Violation101
Overall StudyReason unknown100
Overall StudyWithdrawal by Subject012

Baseline characteristics

Characteristic0.8 mg Nicotine0.12 mg Nicotine0.03 mg NicotineTotal
Age, Continuous35.90 years
STANDARD_DEVIATION 10.82
35.18 years
STANDARD_DEVIATION 11.13
35.65 years
STANDARD_DEVIATION 11.21
35.59 years
STANDARD_DEVIATION 11.05
Cigarettes Per Day19.63 Cigarettes Per Day
STANDARD_DEVIATION 10.33
19.54 Cigarettes Per Day
STANDARD_DEVIATION 10.56
19.91 Cigarettes Per Day
STANDARD_DEVIATION 10.84
19.71 Cigarettes Per Day
STANDARD_DEVIATION 10.58
Race/Ethnicity, Customized
Latino
7 Participants8 Participants8 Participants23 Participants
Race/Ethnicity, Customized
Non-Latino Black
24 Participants25 Participants19 Participants68 Participants
Race/Ethnicity, Customized
Non-Latino Other
12 Participants18 Participants16 Participants46 Participants
Race/Ethnicity, Customized
Non-Latino White
207 Participants183 Participants240 Participants630 Participants
Race/Ethnicity, Customized
Unknown
4 Participants1 Participants3 Participants8 Participants
Region of Enrollment
United States
254 participants235 participants286 participants775 participants
Sex: Female, Male
Female
184 Participants167 Participants200 Participants551 Participants
Sex: Female, Male
Male
70 Participants68 Participants86 Participants224 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
deaths
Total, all-cause mortality
0 / 2541 / 2351 / 286
other
Total, other adverse events
241 / 254203 / 235226 / 286
serious
Total, serious adverse events
13 / 2544 / 23513 / 286

Outcome results

Primary

Cigarettes Per Day (CPD)

Participant reported number of cigarettes smoked per day at Week 12

Time frame: 12 weeks

Population: Participants who completed Week 12

ArmMeasureValue (LEAST_SQUARES_MEAN)Dispersion
0.8 mg NicotineCigarettes Per Day (CPD)25.28 cigarettes per dayStandard Error 0.77
0.12 mg NicotineCigarettes Per Day (CPD)19.95 cigarettes per dayStandard Error 0.8
0.03 mg NicotineCigarettes Per Day (CPD)17.74 cigarettes per dayStandard Error 0.74
Comparison: The statistical analysis method was ANCOVA, in order to test for statistically significant differences between group means, while controlling for covariates of interest. It was calculated that 207 subjects per group would be required to have at least 90% power to detect a mean difference of 4.52 CPD between the 0.8 mg and 0.12 mg groups at week 12, with significance level alpha of 0.0167. The significance level reflects the Bonferroni correction needed for testing of all pairwise comparisons.p-value: <0.000195% CI: [-7.41, -3.26]ANCOVA
Comparison: The statistical analysis method was ANCOVA, in order to test for statistically significant differences between group means, while controlling for covariates of interest. It was calculated that 207 subjects per group would be required to have at least 90% power to detect a mean difference of 4.52 CPD between the 0.8 mg and 0.12 mg groups at week 12, with significance level alpha of 0.0167. The significance level reflects the Bonferroni correction needed for testing of all pairwise comparisons.p-value: <0.000195% CI: [-9.51, -5.57]ANCOVA

Source: ClinicalTrials.gov · Data processed: Feb 22, 2026